New Delhi: Drug firm Zydus Cadila today said it has launched Zolmitriptan orally disintegrating tablets, a migraine drug, in the American market after getting approval from the US health regulator.
The company announced the launch of Zolmitriptan orally disintegrating tablets in the US market after receiving final approval from the US Food and Drug Administration (USFDA), Zydus Cadila said in a statement.
The company is marketing the product in the strengths of 2.5 mg and 5 mg in the US market, it added.
As per IMS sales data, the sales of Zolmitriptan, used in the treatment of migraine, was estimated at USD 175 million in 2012.
Zydus Cadila group now has 79 approvals in the US market.